Skip to content
Who We Are
Science
Technology Platform
Drug candidates
News
Contact
Who We Are
Science
Technology Platform
Drug candidates
News
Contact
FR
EN
23 July 2025
SQY Therapeutics Receives Orphan Drug Designation from the European Medicines Agency for SQY51 for the Treatment of Duchenne Muscular Dystrophy
Read article
4 March 2025
SQY Therapeutics announces completion of the first part of phase 1/2a clinical trial AVANCE-1 and initiation of the second part with recurrent administrations of SQY51
5 November 2024
SQY Therapeutics receives FDA orphan drug designation for SQY51 for the treatment of Duchenne Muscular Dystrophy
23 February 2023
SQY Therapeutics announces the launch of the first clinical trial for Duchenne Muscular Dystrophy by “exon skipping” with an antisense oligonucleotide of the tricyclo-DNA class.
